February 24, 2026 4:49pm

For now … the key is to know why the session evolved from today to tomorrow

As market rebounds from Ai fear even as earnings reveal their LPS <losses-per-share>

RMi collects, curates, interprets and disseminates cell and gene therapy sector (C&GT) fact-based news, trustable and verified intel of share pricing data bridging the gap to an investment decision

Never leave a retail investor uninformed!  It’s not always time to buy or sell; but it is time to KNOW why!

I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others will not say or write about – facts in evidence!  I’m NOT at all writing a doom-and-gloom predictions as I am more frequently right than consequentially wrong; I am mostly EARLY in my prognostications!

Tuesday’s RMi Pre-opening: Recoil, ricochet with a cold shiver … https://www.regmedinvestors.com/articles/14325

 

I chose to speak-up when many analysts, brokers and commentators have shut-up!

 

Tuesday: The Dow closed UP +370.44 points or +0.76%, the S&P closed UP +52.32 points or +0.77% while the Nasdaq closed UP +236.409 points or +1.05%

  • Theme of the session: Ai fears ease as software/tech firms share pricing move slowly upward

Tuesday’s (my) 40-company covered sector’s advance/decline line opened positive with 22 incliners, 15 decliners and 3 flats, ending with a positive close of 32 incliners, 5 decliners and 3 flats

Henry’omics: We need to more than consider the macro-economic environment to comprehend the cause and effect of the macro versus micro data affecting “our” universe of cell and gene therapy (C&GT) sector

  • The Conference Board consumer confidence index rose to 91.2, up 2.2 points from the upwardly revised January level and better than the consensus estimate for 86.8. The Present Situation index moved lower though the expectations index improved.
  • The U.S. labor market showed some signs of improvement in the early part of February, according to payrolls processing firm ADP. Private payrolls increased by 12,750 for the week ended Feb. 7, the 4th consecutive improvement over the period week. The total was the best one-week gain since 11/29/25.

The CBOE Fear (VIX) index, Tuesday closed at 19.61, after Monday’s 21.01, Friday’s 19.11, Thursday’s 20.28, Wednesday’s 19.64, and last Tuesday’s 20.35

Metrics: Tuesday …

  • The RUT was up +31.34 points or +1.20%,
  • The XLV was down -0.67 points or -0.42%,
  • The NBI was up +47.71 points or +0.79%;
  • The XBI was up +2.16 points or +1.70%
  • The IWM was up +2.84 or +1.09%;
  • The IBB was up +1.26 points or +0.72%,
  • The VIX was down -1.40 points or -1.40% at to 19.61

 

Q1/26 February – 1 market holiday, 7 negative and 9 positive sessions

  • January – 2 holidays, 2 neutral, 9 negative and 9 positive closes

Q4/25 …

  • December – 1 holiday, 8 positive and 14 negative closes
  • November – 1 holiday, 8 positive and 11 negative closes
  • October -1 neutral, 11 positive and 12 negative closes

 

Tuesday Closing UP (10 of 32) 

  • Vertex (VRTX +$6.42 after Monday’s +$4.11 after Friday’s +$7.63),
  • Beam Therapeutics (BEAM +$3.96 after Monday’s +$0.74 after Friday’s -$0.29),
  • Alnylam Pharmaceuticals (ALNY +$3.50 after Monday’s -$6.84 after Friday’s -$3.18),
  • CRISPR Therapeutics (CRSP +$2.79 after Monday’s +$0.52 after Friday’s -$1.18),
  • Supernus Therapeutics (SUPN +$2.61 after Monday’s -$0.17 after Friday’s -$0.49),
  • IQIA Holdings (IQV +$2.56 after Monday’s -$3.51 after Friday’s -$3.67),
  • BioNTech (BNTX +$0.96 after Monday’s -$0.21),
  • Lenz Therapeutics (LENZ +$0.93 after Monday’s +$0.30 after Friday’s -$0.46),
  • Ionis Pharmaceuticals (IONS +$0.85 after Monday’s +$1.45 after Friday’s +$0.01),
  • Sarepta Therapeutics (SRPT +$0.72 after Monday’s -$0.76 after Friday’s +$0.29),

Flat (3)

  • Harvard Apparatus RT (OTCQB: HRGN)
  • Generation Bio (GBIO) – acquired
  • Vericel (VCEL)

Tuesday’s Closing DOWN (5 of 5): 

  • AxoGen (AXGN -$2.88),
  • uniQure NV (QURE -$0.43 after Monday’s +$1.03 after Friday’s -$0.97),
  • BioLife Solutions (BLFS -$0.23 after Monday’s -$0.21),
  • Mesoblast (MESO -$0.16 after Monday’s -$0.20),
  • Precigen (PGEN -$0.10 after Monday’s -$0.30),

 

The Bottom Line: More of the … WHY

Indexes rose Tuesday, with … software stocks leading the way, surprise, surprise!

  • Still, today and the software’s sea of green doesn’t erase the damage. Most names are still down double digits since the early-February “AI scare” flush.
  • All eyes will be on AI chip heavyweight Nvidia when it posts quarterly results on Wednesday after the market close.
  • Today is a step in the right direction — but bottoming is a process, and the turn often starts when the last weak hands finally throw in the towel. <Yahoo Finance>

Interesting quote, ““It seemed to me that that the market itself was in a sell-first, ask-questions-later mentality. It has been for some time, and that’s why you saw some of even the enterprise software guys take a rather large hit,” Anshul Sharma, chief investment officer at Savvy Wealth, said to CNBC. He added that the day’s moves are “a classic relief rally after that selling.” <CNBC>

  • Sharma also said “that he’s not quite convinced of the narrative that has been recently been circulating on Wall Street that AI is coming to replace a lot of enterprise software right away.”

 

More earnings this week and coming…

Earnings release dates:

  • Tuesday - 2/24 – AxoGen (AXGN), Beam Therapeutics (BEAM) and Supernus Therapeutics (SUPN)
  • Wednesday – 2/25 – MiMedx (MDXG), Ionis Pharmaceuticals (IONS) and Sarepta Therapeutics (SRPT)
  • Thursday – 2/26 – Intellia Therapeutics (NTLA), Wave Life Sciences (WVE), Vericel (VCEL) and BioLife Solutions (BLFS)

 

RISK is always a factor remaining below the surface …  boiled-up as slight shocks of profiteering on upsides shook but not rocked the C&GT sector and markets!

  • As I had also written, cash is king for investors who want to keep some liquidity and avoid having to sell in a down market,

 

February – 4th week

  • 2/24 - Tuesday closed positive with 32 incliners, 5 decliners and 3 flats
  • 2/23 - Monday closed positive with 24 incliners, 13 decliners and 3 flats

February – 3rd week

  • 2/20 - Friday closed negative with 13 incliners, 26 decliners and 1 flat
  • 2/19 – Thursday closed positive with 25 incliners, 12 decliners and 3 flats
  • 2/18 - Wednesday closed positive with 30 incliners, 8 decliners and 2 flats
  • 2/17 – Tuesday closed positive with 27 incliners, 11 decliners and 2 flats
  • 2/16 – Monday was market holiday

 

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

 

Why do I keep repeating, framed in a different para, so investors can make the connection

The top three (3) performing in the session:    Winners

  • Tuesday: Vertex (VRTX), Beam Therapeutics (BEAM) and Alnylam Pharmaceuticals (ALNY)  
  • Monday: Vertex (VRTX), Ionis Pharmaceuticals (IONS) and uniQure NV (QURE)
  • Friday: Vertex (VRTX), Ultragenyx Pharmaceuticals (RARE) and Wave Life Sciences (WVE)

The worst three (3) in the session: Losers

  • Tuesday: AxoGen (AXGN), uniQure NV (QURE), and BioLife Solutions (BLFS)
  • Monday: Alnylam Pharmaceuticals (ALNY), IQIA Holdings (IQV) and Sarepta Therapeutics (SRPT)
  • Friday: IQIA Holdings (IQV), Alnylam Pharmaceuticals (ALNY) and CRISPR Therapeutics (CRSP)

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.